Simulations Tools that connect to the Rice cluster will be inoperable due to system upgrades from Tuesday, May 29th, 2018, 8:00am ET to Wednesday May 30, 2018, 5:00pm ET. We apologize for any inconvenience.
Find information on common issues.
Ask questions and find answers from other users.
Suggest a new site feature or improvement.
Check on status of your tickets.
Ethics, Environment, and Nanotechnologies
out of 5 stars
02 Apr 2008 | | Contributor(s):: Barbara Karn
Karn represented EPA on the interagency Nanoscale Science, Engineering, and Technology subcommittee (NSET) of the White House Office of Science and Technology Policy, National Science and Technology Council.Karn holds a Ph.D. in biology and environmental science from Florida International...
History of Research with Human Subjects: Ethical Steps Forward and Back
29 Apr 2009 | | Contributor(s):: Jason T. Eberl
Nanotechnologies and Medical Ethics
02 Apr 2008 | | Contributor(s):: Nigel M. de S. Cameron
Purdue Bioethics Seminar Series
01 Apr 2008 | | Contributor(s):: Jonathan Beever, Nicolae Morar
How do biotechnologies challenge our social boundarires?The Purdue Bioethics Seminar Series seeks to continue to press the issue of ethics in science and technology here at Purdue. We intend to build opportunities for engagement between philosophy, policy, and science at a campus-wide level and...
Toward Anticipatory Governance
25 Sep 2007 |
The Center for Nanotechnology in Society at Arizona State University (CNS-ASU) is an NSF-funded center, created in October 2005, for research, education and outreach on the societal aspects of nano-scale science and engineering (NSE). CNS-ASU involves the collaboration of scores of faculty,...
WALLA Lecture: Social Implications of Nanoscience
05 May 2010 | | Contributor(s):: Ronald F. Turco
"Who Owns Truth?" - Biomedical Research in a Health Policy Context
30 Mar 2009 | | Contributor(s):: Samuel A. Richmond
This presentation examines a claim made by PhRMA on behalf of pharmaceutical manufacturing companies of America, and the response of the International Committee of Medical Journal Editors (ICMJE) questioning drug company publication policies and practices. Also considered are changes in law...